NUVB Company Profile and Key Details

Q: Who are the executives of NUVB?

Dr. Gary Hattersley Ph.D.Chief Scientific OfficerDr. David C. Hanley Ph.D.Chief Technical Operations OfficerDr. David Liu M.D., Ph.D.Chief Medical OfficerMs. Jennifer A. FoxChief Financial Officer & Sec.Ms. Stacy MarkelChief People OfficerDr. David T. Hung M.D.Founder, Pres, Chief Executive Officer & DirectorMs. Kerry A. WentworthChief Regulatory Officer

NYSE : NUVB

Nuvation Bio

$5.87

0.2+3.53%

At Close 4:00 PM

58.64

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Nuvation Bio Inc. (NUVB) stock surged +3.53%, trading at $5.87 on NYSE, up from the previous close of $5.67. The stock opened at $5.53, fluctuating between $5.48 and $5.91 in the recent session.

Stock Snapshot

5.67

Prev. Close

2.04B

Market Cap

5.4801

Day Low

-13.65

P/E Ratio

-0.43

EPS (TTM)

-0.31

Cash Flow per Share

5.53

Open

347.2M

Number of Shares

5.91

Day High

67.5%

Free Float in %

2.76

Book Value

9.06M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	5.54	5.91	5.48	5.87	10.51M
Jul 07, 2026	5.68	5.89	5.52	5.67	7.14M
Jul 06, 2026	5.77	5.94	5.55	5.60	5.44M
Jul 02, 2026	5.42	5.72	5.39	5.70	6.33M
Jul 01, 2026	5.68	5.92	5.33	5.42	8.35M
Jun 30, 2026	5.67	5.96	5.57	5.68	14.43M
Jun 29, 2026	5.61	5.65	5.39	5.61	8.52M
Jun 26, 2026	5.80	6.08	5.50	5.65	35.18M
Jun 25, 2026	5.62	6.18	5.48	5.81	24.83M
Jun 24, 2026	6.08	6.60	6.08	6.46	9.42M
Jun 23, 2026	5.71	6.09	5.66	6.04	4.6M
Jun 22, 2026	5.64	5.88	5.61	5.76	4.16M
Jun 18, 2026	5.44	5.58	5.33	5.56	4.72M
Jun 17, 2026	5.16	5.36	5.11	5.33	5.41M
Jun 16, 2026	5.15	5.26	5.04	5.12	3.62M
Jun 15, 2026	5.04	5.17	4.87	5.14	4.18M
Jun 12, 2026	4.86	5.21	4.86	4.92	5.25M
Jun 11, 2026	4.55	4.81	4.45	4.76	3.46M
Jun 10, 2026	4.84	4.96	4.52	4.58	6.67M
Jun 09, 2026	5.08	5.64	4.57	4.93	9.71M

Contact Details

New York City, NY 10036

United States

https://www.nuvationbio.com 332 208 6102

About Company

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Stock Peers

MANE

1.45+1.24%

Veradermics, Incorporated$118.25 RCUS

0.01+0.03%

Arcus Biosciences, Inc.$30.26 AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 ANRO

0.39+1.52%

Alto Neuroscience, Inc.$26.09 BHVN

1.09+7.01%

Biohaven Ltd.$16.64 EVMN

-0.09-0.67%

Evommune, Inc.$13.25 DNA

-0.27-2.89%

Ginkgo Bioworks Holdings, Inc.$9.07 EBS

-0.15-1.81%

Emergent BioSolutions Inc.$8.14 ANVS

0.07+3.65%

Annovis Bio, Inc.$1.99 ADCT

-0.07-5.19%

ADC Therapeutics S.A.$1.28

Company Overview

Nuvation Bio Inc. (NYSE:NUVB) closed at $5.87 USD, gaining $0.20 (3.53%) from the previous close of $5.67. The stock is currently mid-range between its 52-week high and low $2.06 and $9.75. With a market capitalization of about $2.04 billion, Nuvation Bio Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.53). Key stats such as the average daily volume over the past year has been around 5.74 million shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Nuvation Bio Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David T. Hung, the company employs approximately 273 people and listed since August 26, 2020. Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.7%, SMA50 -15.75%, SMA200 31.94%). The stock’s 14-day RSI is 46.78 (neutral), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.51% below its high and over 276.62% above its low. Average 10-day trading volume of 8.67 million shares is slightly above the 3-month average of 5.86 million, indicating heightened recent market interest.

Valuation Metrics

Nuvation Bio Inc. trades at a P/E ratio of -13.84, slightly below the S&P 500 average, with a price-to-sales ratio of 14.26 and a price-to-book ratio of 6.39 trading at moderately above to book value. The P/FCF stands at -16.18, also below market averages.

Dividend & Fair Value

Nuvation Bio Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.32. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Nuvation Bio Inc. generated EPS of -$0.64 over the past year. Five-year average earnings growth is -49.14%. Wall Street analysts project EPS growth of 59.61% annually over the next five years. The latest quarter delivered EPS of $0.01. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$22.07. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 9 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $6.00. The high target offers 240.72% upside. The low target suggests 2.21% downside. The mean target is $11.62. This offers 97.96% upside. Nuvation Bio Inc. earnings surprise history is a mixed track record. The quarter that ended May 04, 2026, missed forecasts by -135.66%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 7.14% in March 06, 2025.

Shareholding & Insider Activity

Nuvation Bio Inc. has 341.27 million shares outstanding. The public float is 231.05 million shares, elevated short interest at 32.92% of float. This equals 69.07 million shares. The short ratio is 15.03 days. Institutional investors hold 82.42% of the float. Insiders own 19.03%. Hung David holds 59.28 million shares, Omega Fund V GP Manager, Ltd. has 20.46 million shares and Omega Fund V, L.P. has 20.46 million shares. Over the past six months, insider transactions show net selling. They sold 522.42 thousand shares across 6 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Nuvation Bio has not generated any revenue. Returns are negative, with ROA at -12.20% and ROE at -12.53%.
On valuation metrics, Nuvation Bio trades at a P/E of -13.84, P/S of 14.26 and P/B of 6.39. The current ratio is 7.44 and quick ratio is 7.24. Operationally, the company’s inventory turnover is 0.76 and cash conversion cycle is -134.78 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -12.79.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Nuvation Bio posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $222.00K (margin 0.00%). Operating income was - $99.82M (margin 0.0%). Net income was- $75.80M (EPS - $0.35).
The company ended the quarter with $611.21M in cash and short-term investments, a total debt of $4.01M, and net debt of - $38.64M. Total assets were $621.48M, with equity of $605.12M. Financials further reflected weakness, with operating cash flow of - $68.00M, free cash flow of - $68.07M, and capital expenditures of - $69.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Nuvation Bio Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.13%, with price expected at $6.23 by July 22, 2026, within a range of $5.93 to $6.59 3-Month Outlook: Projected fall of -17.04%, reaching $4.87 by October 06, 2026, with a range of $4.63 to $5.10. 1-Year Outlook: Projected gain of 272.91%, with price at $21.89 by July 08, 2027, within a range of $23.28 to $26.03.

Key Takeaways

Nuvation Bio Inc. (NYSE:NUVB) shares are down -32.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nuvation Bio Inc. trading at a premium to the broader market with a P/E of -13.84. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $10.28, suggesting 75.13% upside. Our AI forecast model points to short-term strength (6.13% over two weeks), a medium-term fall (-17.04% over three months), and a longer-term gain (272.91% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Nuvation Bio Inc. (NUVB) stock price?

Nuvation Bio Inc. (NYSE: NUVB) stock price is $5.87 in the last trading session. During the trading session, NUVB stock reached the peak price of $5.91 while $5.48 was the lowest point it dropped to. The percentage change in NUVB stock occurred in the recent session was 3.53% while the dollar amount for the price change in NUVB stock was $0.20.

NUVB's industry and sector of operation?

The NYSE listed NUVB is part of Biotechnology industry that operates in the broader Healthcare sector. Nuvation Bio Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NUVB?

Dr. Gary Hattersley Ph.D.
Chief Scientific Officer
Dr. David C. Hanley Ph.D.
Chief Technical Operations Officer
Dr. David Liu M.D., Ph.D.
Chief Medical Officer
Ms. Jennifer A. Fox
Chief Financial Officer & Sec.
Ms. Stacy Markel
Chief People Officer
Dr. David T. Hung M.D.
Founder, Pres, Chief Executive Officer & Director
Ms. Kerry A. Wentworth
Chief Regulatory Officer

How NUVB did perform over past 52-week?

NUVB's closing price is 184.95% higher than its 52-week low of $2.06 where as its distance from 52-week high of $9.75 is -39.8%.

How many employees does NUVB have?

Number of NUVB employees currently stands at 273.

Link for NUVB official website?

Official Website of NUVB is: https://www.nuvationbio.com

How do I contact NUVB?

NUVB could be contacted at phone 332 208 6102 and can also be accessed through its website. NUVB operates from 1500 Broadway, New York City, NY 10036, United States.

How many shares of NUVB are traded daily?

NUVB stock volume for the day was 9.06M shares. The average number of NUVB shares traded daily for last 3 months was 5.74M.

What is the market cap of NUVB currently?

The market value of NUVB currently stands at $2.04B with its latest stock price at $5.87 and 347.2M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	273
Beta	1.53
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NUVB Company Profile and Key Details

Nuvation Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Company Overview

Technical Performance

Dividend & Fair Value

Valuation Metrics

Earnings & Analyst Outlook

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights